Symbols

LFMD

LifeMD·NASDAQ

--(--)

LFMD fundamentals

LFMD Q4 2025 Earnings

LifeMD (LFMD) released its earnings on Mar 9, 2026: revenue was 46.87M (YoY -27.06%), beat estimates; EPS was 0.41 (YoY +2150.00%), beat estimates.

Revenue / YoY

46.87M

-27.06%

EPS / YoY

0.41

+2150.00%

Report date

Mar 9, 2026

LFMD Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue $46.9M (+4% YoY), driven by oral Wegovy (80% of new sign-ups) and men's health recovery.
AI & Pharmacy Innovation: Launching AI clinical decision support tool Q2 2026; 503-A compounding pharmacy enables personalized meds with 70% in-house fulfillment.
Women's Health Momentum: Early retention >80%, CAC halved in 30 days; targeting Q4 2026 EBITDA accretion.
2026 Outlook: Full year revenue $220M-$230M, EBITDA $12M-$17M; Q4 2026 run rate targets >$250M revenue, >$25M EBITDA.
Competitive Edge: 50-state provider network, integrated care model, and benefits expansion to 220M lives by Q2 2026.

Earnings

EPS

Revenue

Revenue & Expenses

LFMD has released its 2025 Q4 earnings report, with revenue of 7.08M, reflecting a YoY change of 29.03%, and net profit of 19.94M, showing a YoY change of 531.03%. The Sankey diagram below clearly presents LFMD's revenue sources and cost distribution.

Key Indicators

LifeMD (LFMD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

LifeMD (LFMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

LifeMD (LFMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

LifeMD (LFMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown